SynthesisFrontiers in immunology2023

The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.

Shubin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.